SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF A FOREIGN ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For September 18, 2018

Commission File Number 1-38455

 

 

MorphoSys AG

 

 

Semmelweisstrasse 7

82152 Planegg

Germany

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐            No  ☒

If ‘‘Yes’’ is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

 

 

 

Exhibits

 

99.1    MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-derived Therapeutics

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MORPHOSYS AG (Registrant)
Date: September 18, 2018   By:  

/s/ Jens Holstein

    Name:   Jens Holstein
    Title:   CFO
  By:  

/s/ Hans-Joachim Orlowski

    Name:   Hans-Joachim Orlowski
    Title:   Associate Director Corporate Communications and Investor Relations
MorphoSys (NASDAQ:MOR)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025 Haga Click aquí para más Gráficas MorphoSys.
MorphoSys (NASDAQ:MOR)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025 Haga Click aquí para más Gráficas MorphoSys.